Acceleron to Host Webcast to Review First Quarter 2017 Financial and Operational Results on May 8, 2017
April 26 2017 - 7:00AM
Business Wire
- Management to review highlights from
luspatercept clinical presentations at the 14th International MDS
Symposium -
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapeutics to treat serious and
rare diseases, today announced that the Company will host a live
conference call and webcast on Monday, May 8, 2017 at 8:00 a.m. EDT
to discuss luspatercept Phase 2 data presented at the 14th
International Symposium on Myelodysplastic Syndromes (MDS) and its
first quarter 2017 financial results.
Participants can access the live conference call by dialing
877-312-5848 (domestic) or 253-237-1155 (international) and
referring to the Acceleron Earnings Call.
The live webcast can be accessed on the Investors page of the
Company's website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two
hours after the event on the Acceleron website.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of innovative
therapeutics to treat serious and rare diseases. Its pioneering
research platform leverages the powerful biology behind the body’s
ability to rebuild and repair its own cells and tissues. This
approach to drug discovery has generated four therapeutic
candidates that are currently in clinical trials. The Company’s
lead therapeutic candidate, luspatercept, is being evaluated in
Phase 3 studies for the treatment of the hematologic diseases
myelodysplastic syndromes (MDS) and beta-thalassemia under a global
partnership with Celgene Corp. Acceleron is also advancing clinical
programs in the fields of oncology and neuromuscular diseases and
has a comprehensive preclinical research effort targeting fibrotic
and other serious diseases.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social
Media: @AcceleronPharma and LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170426005270/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Senior
Director, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Apr 2023 to Apr 2024